QUANTUM GENOMICS : Quantum Genomics announces the appointment of Professor Faiez Zannad as its heart failure consultant

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, is announcing its collaboration with Professor Faiez Zannad, acting as a specialized consultant, in order to accelerate its developments in the treatment and prevention of heart failure.

A professor of interventional cardiology at the University of Lorraine (CHU Nancy), medical doctor, cardiologist, doctor of human biology (PhD) and clinical pharmacology, and the holder of a grant from the Oxford Medical Research Council, Professor Faiez Zannad has played a role in many therapeutic advances in the treatment of heart failure. He has conducted and published major clinical studies on mineralocorticoid receptor antagonists, beta blockers, angiotensin II receptor antagonists, direct renin inhibitors and vasopressin antagonists, most of which have resulted in the approval of medicines which have since been recommended by international guidelines.

Coordinator of the Inserm Clinical Investigation Centre at the University of Lorraine (CHU Nancy) and of the Réseau des Centres d'Investigation Clinique Cardiovasculaires, as well as head of the hypertension and heart failure unit of the cardiology department at Institut Lorrain du Cœur et des Vaisseaux (CHU Nancy), he has also served as a specialized consultant for many major pharmaceutical groups, including Amgen, AstraZeneca, Bayer, Eli Lilly, Merck, Novartis, Pfizer and Takeda.

His main areas of research concern heart failure, biomarkers and clinical tests in this domain. As a clinical researcher, he has participated in the creation of a heart failure care network and the development of guidelines for the European Cardiology Society.

On the occasion of this partnership, Lionel Ségard, CEO of Quantum Genomics, stated: "Professor Zannad will work on the implementation of our next Phase IIa clinical study on heart failure in collaboration with our medical director, Doctor Olivier Madonna. Together, they will determine patient typology and the goals to be met for this first study, formulate the protocol and select the international hospital centres where the study will be conducted. Professor Zannad's high level of expertise in this domain is a major asset."

Professor Faiez Zannad added, "Quantum Genomics' original mode of operation is of great interest for the creation of a new, complementary therapeutic approach to heart failure. There is a strong need for this - in the medical community and for patients - and I hope that the new therapeutic class of BAPAIs will help significantly improve patient care."

CONTACTS Quantum Genomics Lionel Ségard Chairman & Chief Executive Officer +33 1 85 34 77 77   Quantum Genomics Marc Karako CFO – Investor Relations +33 1 85 34 77 75 marc.karako@quantum-genomics.com   ACTUS finance & communication Jean-Michel Marmillon Press Relations +33 1 53 67 36 73 jmmarmillon@actus.fr

 

ABOUT QUANTUM GENOMICS Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure. Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, Inserm, CNRS and the University of Paris Descartes. Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).

---

Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués

---

Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-40848-QGC_CP_Recrutement_FZannad_27072015_VDEF_EN.pdf